Difference between revisions of "WHIM syndrome"
Jump to navigation
Jump to search
Warner-admin (talk | contribs) m (Text replacement - "5 PubMed" to "5/ PubMed") |
Warner-admin (talk | contribs) m (Text replacement - ", <20 p" to ", fewer than 20 p") |
||
| Line 20: | Line 20: | ||
|- | |- | ||
|[https://www.ncbi.nlm.nih.gov/pmc/articles/pmc6425947/ McDermott et al. 2019] | |[https://www.ncbi.nlm.nih.gov/pmc/articles/pmc6425947/ McDermott et al. 2019] | ||
| − | |style="background-color:#ffffbe"|Pilot, | + | |style="background-color:#ffffbe"|Pilot, fewer than 20 pts |
|- | |- | ||
|} | |} | ||
Revision as of 06:44, 18 July 2023
Section editor transclusions WHIM: Warts, Hypogammaglobulinemia, Infections, Myelokathexis
1 regimens on this page
1 variants on this page
|
All lines of therapy
Plerixafor monotherapy
References
- McDermott DH, Pastrana DV, Calvo KR, Pittaluga S, Velez D, Cho E, Liu Q, Trout HH 3rd, Neves JF, Gardner PJ, Bianchi DA, Blair EA, Landon EM, Silva SL, Buck CB, Murphy PM. Plerixafor for the treatment of WHIM syndrome. N Engl J Med. 2019 Jan 10;380(2):163-170. link to original article link to PMC article PubMed